News
PRTA
20.04
-0.30%
-0.06
Weekly Report: what happened at PRTA last week (0513-0517)?
Weekly Report · 6d ago
Prothena: Statement of changes in beneficial ownership of securities
Press release · 05/17 21:25
Prothena Shareholders Approve Incentives and Governance Measures
TipRanks · 05/17 20:22
New Forecasts: Here's What Analysts Think The Future Holds For Prothena Corporation plc (NASDAQ:PRTA)
Prothena Corporation plc (NASDAQ:PRTA) analysts have upgraded this year's statutory forecasts for the company. The analysts are now more bullish on the company's long-term prospects. The consensus estimate for Prothena's revenues is now for revenues of US$15m in 2024. However, the company is expected to grow slower than the wider industry.
Simply Wall St · 05/14 10:24
Weekly Report: what happened at PRTA last week (0506-0510)?
Weekly Report · 05/13 09:16
Cantor picks 14 undervalued biotech stocks worth a second look
Healthcare Cantor picks 14 undervalued biotech stocks worth a second look. All of the picks were down more than 20% year-to-date, as of May 6. Cantor Fitzgerald has selected its 14 top picks for biotech stocks that it regards as significantly undervalued.
Seeking Alpha · 05/12 15:00
Piper Sandler Sticks to Their Buy Rating for Prothena (PRTA)
TipRanks · 05/10 12:05
Buy Rating Affirmed for Prothena Amid Strong Pipeline and Financial Health
TipRanks · 05/10 05:30
Prothena Corporation PLC - Form 10-Q - Quarterly Report for the Quarter Ended March 31, 2024
Press release · 05/10 02:03
Prothena Is Maintained at Market Outperform by JMP Securities
Dow Jones · 05/09 18:51
Prothena Price Target Cut to $83.00/Share From $85.00 by JMP Securities
Dow Jones · 05/09 18:51
JMP Securities Maintains Market Outperform on Prothena Corp, Lowers Price Target to $83
Benzinga · 05/09 18:41
Prothena Price Target Cut to $84.00/Share From $90.00 by HC Wainwright & Co.
Dow Jones · 05/09 18:07
Prothena Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 05/09 18:07
HC Wainwright & Co. Maintains Buy on Prothena Corp, Lowers Price Target to $84
Benzinga · 05/09 17:57
Buy Rating Affirmed: Prothena’s Prasinezumab Shows Promise in Slowing Parkinson’s Progression
TipRanks · 05/09 12:25
RBC Capital Sticks to Their Hold Rating for Prothena (PRTA)
TipRanks · 05/09 10:53
Analysts Are Bullish on These Healthcare Stocks: Paragon 28 (FNA), Prothena (PRTA)
3 analysts just weighed in on Paragon 28, Prothena and Mirum Pharmaceuticals with bullish sentiments. JMP Securities analyst David Turkaly reiterated a Buy rating on paragon 28 today and set a price target of $20.00. The analysts also reiterated Buy ratings on mirum pharmaceuticals and prothena.
TipRanks · 05/09 04:50
PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024
Prothena Corp reported earnings per share of -$1.34 for the first quarter of 2024. The company reported revenue of $50,000. This was 97.70% worse than the analyst estimate for revenue of $2.17 million.
Investorplace · 05/09 02:56
Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates
NASDAQ · 05/08 22:10
More
Webull provides a variety of real-time PRTA stock news. You can receive the latest news about Prothena through multiple platforms. This information may help you make smarter investment decisions.
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.